There remains an important need to better understand and predict the renal effects of HBOCs in recipients that may be affected by pre-existing conditions including advanced age, diabetes, infection, ischemia, and chronic disease that render kidneys more susceptible to Hb or heme toxicity (26, 48–50). This evidence concerns the gene GSTM1 and infection.